CY1109464T1 - Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων - Google Patents

Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων

Info

Publication number
CY1109464T1
CY1109464T1 CY20091101035T CY091101035T CY1109464T1 CY 1109464 T1 CY1109464 T1 CY 1109464T1 CY 20091101035 T CY20091101035 T CY 20091101035T CY 091101035 T CY091101035 T CY 091101035T CY 1109464 T1 CY1109464 T1 CY 1109464T1
Authority
CY
Cyprus
Prior art keywords
animals
microm
day
nucleic acid
antisense
Prior art date
Application number
CY20091101035T
Other languages
English (en)
Inventor
Salman Al-Mahmood
Original Assignee
Gene Signal International Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Signal International Sa filed Critical Gene Signal International Sa
Publication of CY1109464T1 publication Critical patent/CY1109464T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

Η εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αναστέλλουν τη δημιουργία τριχοειδών σωλήνων από τα ενδοθηλιακά κύτταρα, η οποία περιλαμβάνει τουλάχιστον ένα ολιγονουκλεοτίδιο το οποίο μπορεί να αναστείλει την έκφραση της IRS-1 πρωτεΐνης. Σύμφωνα με την εφεύρεση, τα ολιγονουκλεοτίδια παρουσιάζονται ως αντιαγγειογενετικοί παράγοντες. Τέτοιες φαρμακευτικές συνθέσεις είναι ιδιαιτέρως χρήσιμες στη θεραπεία παθήσεων που σχετίζονται με αγγειογενέσεις.
CY20091101035T 2001-06-14 2009-10-07 Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων CY1109464T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107805A FR2826010B1 (fr) 2001-06-14 2001-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
EP02751246A EP1409672B1 (fr) 2001-06-14 2002-06-14 Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires

Publications (1)

Publication Number Publication Date
CY1109464T1 true CY1109464T1 (el) 2014-08-13

Family

ID=8864317

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101035T CY1109464T1 (el) 2001-06-14 2009-10-07 Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων

Country Status (13)

Country Link
US (3) US7417033B2 (el)
EP (2) EP1409672B1 (el)
JP (1) JP4153421B2 (el)
AT (1) ATE435911T1 (el)
AU (1) AU2002345669B9 (el)
CA (1) CA2451874C (el)
CY (1) CY1109464T1 (el)
DE (1) DE60232883D1 (el)
DK (1) DK1409672T3 (el)
ES (1) ES2331835T3 (el)
FR (1) FR2826010B1 (el)
PT (1) PT1409672E (el)
WO (1) WO2002103014A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931993A2 (en) * 2005-09-14 2008-06-18 Medizinische Universität Wien Means and methods for diagnosing endometriosis
US8032556B1 (en) * 2008-03-07 2011-10-04 Symantec Corporation Systems and methods for user profile data delivery
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8470997B2 (en) 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
EP2418279A1 (en) * 2010-08-10 2012-02-15 Gene Signal International SA Injectable pharmaceutical composition for preventing, stabilising and/or inhibiting pathological neovascularization-related conditions
EP2540828A1 (en) 2011-06-30 2013-01-02 Gene Signal International SA Composition comprising inhibitors of IRS-1 and of VEGF
JP6159720B2 (ja) 2011-06-30 2017-07-05 ジーン シグナル インターナショナル ソシエテ アノニム Ｉｒｓ−１およびｖｅｇｆの阻害剤を含む組成物
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
US9359604B2 (en) 2012-07-03 2016-06-07 Gene Signal International Sa Inhibitor of IRS-1 for treating skin disorders
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572508A4 (en) * 1991-01-18 1995-03-29 Joslin Diabetes Center Inc NUCLEIC ACID ENCODING THE INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES AND THERAPY ASSOCIATED WITH IRS-1 METABOLISM.
FR2733913B1 (fr) * 1995-05-09 1997-08-01 Sanofi Sa Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
EP1010433A4 (en) * 1997-09-29 2004-09-22 Daiichi Seiyaku Co MEDICINE FOR DISEASES CAUSED BY INSULIN RESISTANCE
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
AU4614600A (en) * 1999-05-18 2000-12-05 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene

Also Published As

Publication number Publication date
US20040162257A1 (en) 2004-08-19
PT1409672E (pt) 2009-11-04
DE60232883D1 (de) 2009-08-20
WO2002103014A2 (fr) 2002-12-27
EP2166095A2 (fr) 2010-03-24
CA2451874C (fr) 2013-07-30
DK1409672T3 (da) 2009-11-09
FR2826010A1 (fr) 2002-12-20
AU2002345669B2 (en) 2006-02-02
US20080293658A1 (en) 2008-11-27
US8828959B2 (en) 2014-09-09
EP2166095A3 (fr) 2012-01-04
ATE435911T1 (de) 2009-07-15
WO2002103014A3 (fr) 2004-02-26
EP1409672B1 (fr) 2009-07-08
US7855184B2 (en) 2010-12-21
AU2002345669B9 (en) 2006-06-29
FR2826010B1 (fr) 2005-02-25
ES2331835T3 (es) 2010-01-18
US7417033B2 (en) 2008-08-26
CA2451874A1 (fr) 2002-12-27
US20090082292A1 (en) 2009-03-26
JP4153421B2 (ja) 2008-09-24
EP1409672A2 (fr) 2004-04-21
JP2004538272A (ja) 2004-12-24

Similar Documents

Publication Publication Date Title
CY1109464T1 (el) Αντισυνθετικα ολιγονουκλεοτιδια ικανα να αναστειλουν την δημιουργια τριχοειδων σωληνων
Wang et al. Transforming growth factor β plays an important role in enhancing wound healing by topical application of Povidone-iodine
Kubinova et al. Non-thermal air plasma promotes the healing of acute skin wounds in rats
Rasika et al. BDNF mediates the effects of testosterone on the survival of new neurons in an adult brain
George et al. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats
Qiu et al. IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling
Bilang-Bleuel et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
Luo et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface
Elgharably et al. A modified collagen gel enhances healing outcome in a preclinical swine model of excisional wounds
DE60216939T2 (de) Verwendung von plasminogen zur herstellung von zerbrochenen trommelfellen
Yun et al. STAT3 activation in microglia exacerbates hippocampal neuronal apoptosis in diabetic brains
Chakrabarti et al. bFGF and collagen matrix hydrogel attenuates burn wound inflammation through activation of ERK and TRK pathway
Kandasamy et al. Transforming Growth Factor‐Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington′ s Disease
Ricardo et al. Angiotensinogen and AT1 antisense inhibition of osteopontin translation in rat proximal tubular cells
EP3007716B1 (en) Tetrapeptides derived from human c-x-c chemokines useful for treatment of various skin conditions
Cichy et al. Stimulatory effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells.
Wei et al. Angiogenesis and stem cell transplantation as potential treatments of cerebral ischemic stroke
Zolle et al. Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP
de Oliveira et al. Adjunctive effect of antimicrobial photodynamic therapy in induced periodontal disease. Animal study with histomorphometrical, immunohistochemical, and cytokine evaluation
Tanios et al. Diabetes and impaired fracture healing: a narrative review of recent literature
Xu et al. Sodium tanshinone IIA sulfonate protects mice from ConA-induced hepatitis via inhibiting NF-κB and IFN-γ/STAT1 pathways
Bothwell Neurotrophin function in skin
US10758559B1 (en) Targeting cathepsin K to facilitate wound healing
Guttridge et al. Protease nexin-1, a thrombin inhibitor, is regulated by interleukin-1 and dexamethasone in normal human fibroblasts.
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물